Overview

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The phase I/II clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of ICP-022.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beijing InnoCare Pharma Tech Co., Ltd.